Genes and structure of selected cytokines involved in pathogenesis of psoriasis

Folia Histochemica et Cytobiologica

Volumn 46, Issue 1, 2008, Pages 11-21

  Pietrzak, Aldona ^a   Zalewska, Anna ^b   Chodorowska, Grazyna ^a   Nockowski, Piotr ^c   Michalak Stoma, Anna ^a   Osemlak, Paweł ^a   Krasowska, Dorota ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Interleukins; Psoriasis; Receptors; Skin disease

Indexed keywords

CYTOKINE; CYTOKINE RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 19; INTERLEUKIN 2; INTERLEUKIN 20; INTERLEUKIN 23; INTERLEUKIN 4; INTERLEUKIN 6; INTERLEUKIN 7; INTERLEUKIN 8; TUMOR NECROSIS FACTOR;

CYTOKINE RELEASE; GENE LOCATION; GENE LOCUS; GENE STRUCTURE; GENETIC IDENTIFICATION; GENETIC SELECTION; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; MOLECULAR MECHANICS; MOLECULAR WEIGHT; PATHOGENESIS; PSORIASIS; REVIEW; ANIMAL; CHEMISTRY; GENETICS; PATHOLOGY;

ANIMALS; CYTOKINES; HUMANS; PSORIASIS; RECEPTORS, CYTOKINE;

EID: 41649091472     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-008-0002-y     Document Type: Review

References (160)

1. Chodorowska G. Plasma concentrations of IFN-γ and TNF-α in psoriatic patients before and after local treatment with dithranol ointment. J Eur Acad Dermatol Venereol. 1998;10: 147-151.
2. Janowski K. Personality components of doping with stress in psoriatic patients (Polish). Lublin:Polihymnia, 2006.
3. Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest. 2004;113:1664-1675.
4. Swanbeck G, Inerot A, Martinsson T, Wahlström J. A population genetic study of psoriasis. Br J Dermatol. 1994;131:32-39.
5. Elder JT, Nair RP, Voorhees JJ. Epidemiology and the genetics of psoriasis. J Invest Dermatol. 1994;102:24S-27S.
6. Gudjonsson JE, Johnston A, Sigmundsdottir H, Valdimarsson H. Immunopathogenic mechanisms in psoriasis. Clin Exp Immunol. 2004;135:1-8.
7. Burden AD, Javed S, Bailey M, Hodgins M, Connor M, Tillman D. Genetics of psoriasis: paternal inheritance and a locus on chromosome 6p. J Invest Dermatol. 1998;110:958-960.
8. Brandrup F, Holm N, Grunnet N, Hennigsen K, Hansen HE. Psoriasis in monozygotic twins: variations in expression in individuals with identical genetic constitution. Acta Derm Venereol. 1982;62:229-236.
9. Suarez-Almazor ME, Russell AS. The genetics of psoriasis. Haplotype sharing in siblings with the disease. Arch Dermatol. 1990;126:1040-1042.
10. Toruniowa B, Kadziela-Wypyska G, Urban J. Clinical course of psoriasis In children hospitalized at the Department of Dermatology, Medical Academy In Lublin between 1980-1990. (Polish) Przegl Dermatol 1992;79:273-278.
11. Grossman RM, Krueger J, Yourish D, et al. Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Natl Acad Sci USA. 1989;86:6367-6371.
12. Krueger GG, Duvic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol. 1994;102,14S-18S.
13. Naldi L, Parazzini F, Peli L, Chatenoud L, Cainelli T. Dietary factors and the risk of psoriasis. Result of an Italian case control study. Br J Dermatol. 1996;134:101-106.
14. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741.
15. Saneczko F, Kaszuba A, Trznadel-Budźko E. Human leukocyte antigens (HLA) in psoriasis. (Polish) Pol Merk Lek. 1997;3:210-212.
16. Allen MH, Veal C, Faassen A, et al. A non - HLA gene within the MHC in psorisis. Lancet. 1999;353:1589-1590.
17. Ahnini RT, Camp NJ, Cork MJ, et al. Novel genetic association between the corneodesmosin (MHC S) gene and susceptibility to psoriasis. Hum Mol Genet. 1999;8:1135-1140.
18. Enerbäck C, Martinsson T, Inerot A, et al. Significantly earlier age at onset for the HLA-Cw6-positive than for the Cw6-negative psoriatic sibling. J Invest Dermatol. 1997;109:695-696.
19. Kaszuba A, Saneczko F, Trznadel-Budźko E. Psoriasis and genom. (Polish). Post Dermatol. 1998;15:217-223.
20. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol. 1985;13:450-456
21. Liu Y, Krueger JG, Bowcock AM. Psoriasis: genetic associations and immune system changes. Genes and Immunity. 2007;8:1-12.
22. Kirby B, Griffiths CEM. Psoriasis: the future. Br J Dermatol. 2001;144;suppl. 58:37-43
23. Hensler T. Genetics of psoriasis. Arch Dermatol Res. 1998; 290:463-476.
24. Jullien D, Barker JN. Genetics of psoriasis. J Eur Acad Dermatol Venereol. 2006;20;suppl. 2:42-51.
25. Elder JT, Cluster 17 Collaboration. Fine mapping of the psoriasis susceptibility gene PSORS1: a reassessment of risk associated with a putative risk haplotype lacking HLA-Cw6. J Invest Dermatol. 2005;124:921-930.
26. Korendowych E, Ravindran J, Owen PA, Carmichael CR, McHugh NJ, Dawkins RL. Disease-specific alleles of the MHC class I related gene, MICA, are associated with type I psoriasis and psoriatic arthritis. Br J Dermatol. 2006;154: 154.
27. Szczerkowska-Dobosz A. Report from the IVth Psoriasis Congress from gene to clinic. London, 1-3.12.2005. (Polish) Post Dermatol Alergol. 2006;23:42-44.
28. Veal CD, Clough RL, Barber RC, et al. Identification of a novel psoriasis susceptibility locus at 1p and evidence of epistasis between PSORS1 and candidate loci. J Med Genet 2001;38:7-13.
29. Bhalerao J, Bowcock AM. The genetics of psoriasis: a complex disorder of the skin and immune system. Hum Mol Genet. 1998;7:1537-1545.
30. Capon F, Novelli G, Semprini S, et al. Searching for psoriasis susceptibility genes in Italy: genome scan and evidence for a new locus on chromosome 1. J Invest Dermatol. 1999;112: 32-35.
31. Trembath RC, Clough RL, Rosbotham JL, et al. Identification of a major susceptibility locus on chromosome 6p and evidence for further disease loci revealed by a two stage genome-wide search in psoriasis. Hum Mol Genet. 1997;6:813-820.
32. Samuelsson L, Enlund F, Torinsson A, et al. A genome-wide search for genes predisposing to familial psoriasis by using a stratification approach. Hum Genet. 1999;105:523-529.
33. Enlund F, Samuelsson L, Enerback C, et al. Psoriasis susceptibility locus in chromosome region 3q 21 identified in patients from southwest Sweden. Eur J Hum Genet. 1999;7: 783-790.
34. Zhang XJ, He PP, Wang ZX, et al. Evidence for a major psoriasis susceptibility locus at 6p21(PSORS1) and a novel candidate region at 4q31 by genome-wide scan in Chinese Hans. J Invest Dermatol. 2002;119:1361-1366.
35. Sagoo GS, Tazi-Ahnini R, Barker JW, et al. Meta-analysis of genome-wide studies of psoriasis susceptibility reveals linkage to chromosomes 6p21 and 4q28-q31 in Caucasian and Chinese Hans population. J Invest Dermatol. 2004;122:1401-1405.
36. Matthews D, Fry L, Powles A, et al. Evidence that a locus for familial psoriasis maps to chromosome 4q. Nat Genet. 1996;14:231-233.
37. Foerster J, Nolte I, Junge J, et al. Haplotype sharing analysis identifies a retroviral dUTPase as a candidate susceptibility gene for psoriasis. J Invest Dermatol. 2005;124:99-102.
38. Foerster J, Nolte I, Schweiger S, et al. Evaluation of the IRF-2 gene as a candidate for PSORS3. J Invest Dermatol. 2004;122:61-64.
39. Lee YA, Ruschendorf F, Windemuth C, et al. Genomewide scan in German families reveals evidence for a novel psoriasis -susceptibility locus on chromosome 19p13. Am J Hum Genet. 2000;67:1020-1024.
40. Nair RP, Henseler T, Jenisch S, et al. Evidence for two psoriasis susceptibility loci (HLA and 17q) and two novel candidate regions (16q and 20 p) by genome-wide scan. Hum Mol Genet. 1997;6:1349-1356.
41. Karason A, Gudjonsson JE, Upmanyu R, et al. A susceptibility gene for psoriatic arthritis maps to chromosome 16 q: evidence for imprinting. Am J Hum Genet. 2003;72:125-131.
42. Tomfohrde J, Silverman A, Barnes R, et al. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 1994;264:1141-1145.
43. Zheng J, Jin S, Shi R. Confirmation of PSORS psoriasis susceptibility loci in a Chinese population. Arch Dermatol Res. 2003;295:14-18.
44. Asumalahti K, Laitinen T, Lahermo P, et al. Psoriasis susceptibility locus on 18 p revealed by genome scan in Finnish families not associated with PSORS1. J Invest Dermatol. 2003; 121:735-740.
45. Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature. 2005;437:369-375.
46. Nair RP, Stuart P, Henseler T, et al, Localization of psoriasis-susceptibility locus PSORS1 to a 60-kb interval telomeric to HLA-C. Am J Hum Genet. 2000;66:1833-1844.
47. Nicklin MJH, Barton JL, Nguyen M, FitzGerald MG, Duff GW, Kornman K. A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics. 2002;79:718-725.
48. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol. 2002;14:117-122.
49. Fletcher M, Goldstein AL. Recent advances in the understanding of the biochemistry and clinical pharmacology of interleukin-2. Lymphokine Res. 1987;6:45-57.
50. Frazer KA, Ueda Y, Zhu Y, et al. Computional and biological analysis of 680 kb of DNA sequence from the human 5q31 cytokine gene cluster region. Genome Res. 1997;7:495-512.
51. Keegan AD. IL-4. In: Oppenheim JJ et al., Eds. Cytokine reference. T.1, San Diego: Academic Press, 2000;127.
52. Kishimoto T. The biology of interleukin-6. Blood. 1989; 74:1-10.
53. Le J, Vilček J. Interleukin-6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest. 1989;61:588-602.
54. Szepietowski JC, Bielicka E, Nockowski P, Noworolska A, Wasik F. Increased interleukin-7 levels in the sera of psoriatic patients: Lack of correlations with interleukin-6 levels and disease intensity Clin Exp Dermatol. 2000;25:643-647.
55. Mc Kinley D, Wu Q, Yang-Feng T, Yang YC. Genomic sequence and chromosomal location of human interleukin-11 gene (IL-11). Genomics. 1992;13:814-819.
56. Robak T. Biologia i farmakologia cytokin. Warszawa: Wydawnictwo Naukowe PWN, 1995.
57. Sutherland GR, Baker E, Fernandez KE, et al. The gene for human interleukin 7 (IL7) is at 8q12-13. Hum Genet. 1989; 82:371-372.
58. Iizasa H, Matsushima K. IL-8. In: Oppenheim JJ et al., Eds. Cytokine reference. T.1, San Diego: Academic Press, 2000;1061-1067.
59. Gallagher G, Dickensheets H, Eskdale J, et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun. 2000;1:442-450.
60. Fickenscher H, Hor S, Kupers H, Knappe A, Wittmann S, Sticht H. The interleukin-10 family of cytokines. Trends Immunol. 2002;23:89-96.
61. Sieburth D, Jabs EW, Warrington JA, et al. Assignment of genes encoding a unique cytokine (IL-12) composed of two unrelated subunits to chromosomes 3 and 5. Genomics. 1992; 14:59-62.
62. Litjens NH, van der Plas MJ, Ravensbergen B, et al. Psoriasis is not associated with IL-12p70/IL-12p40 production and IL12B promoter polymorphism. J Invest Dermatol. 2004;122: 923-926.
63. NCBI Entrez Gene. IL23A interleukin 23, alpha subunit p19 [online]. [18.04.2007].
64. Krause H, Jandrig B, Wernicke C, Bulfone-Paus S, Pohl T, Diamantstein T. Genomic structure and chromosomal localization of the human interleukin 15 gene (IL-15). Cytokine. 1996;8:667-674.
65. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev. 2003;14:155-174.
66. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity. 2004;21:467-476.
67. Goetz FW, Planas JV, MacKenzie S. Tumor necrosis factor. Dev Comp Immunol. 2004;28:487-495.
68. Makhatadze NJ. Tumor Necrosis Factor Locus: Genetic Organisation and Biological Implications. Human Immunol. 1998;59:571-579.
69. Trent JM, Olson S, Lawn RM. Chromosomal localization of human leukocyte, fibroblast, and immune interferon genes by means in situ hybridization. Proc Natl Acad Sci USA. 1982;79:7809-7813.
70. Bureau JF, Bihl F, Brahic M, Paslier DL. The gene coding for interferon-γ is linked to the D12S335 and D12S313 microsatellites and to the MDM2 gene. Genomics. 1995;28: 109-112.
71. Wojas-Pelc A, Ciszek M, Kurnyta M, Marcinkiewicz J. Cytokine network in psoriasis. Cross-talk between keratinocytes and cells of the skin immune system. Centr Eur J Immunol. 2006;31:111-116.
72. Uyemura K, Yamamura M, Fivenson DF, Modlin RL, Nickoloff BJ. The cytokine network in lesional and lesion-free psoriatic skin is Characterized by a T-helper type 1 cell-mediated response. J Invest Dermatol. 1993;101:701-705.
73. Schlaak JF, Buslau M, Jochum W, et al. T cells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol. 1994;102:145-149.
74. Barna M, Snijdewint FGM, Van der Heijden FL, Bos JD, Kapsenberg ML. Characterization of lesional psoriatic skin T lymphocyte clones. Acta Derm Venereol Suppl (Stockh). 1994;186:9-11.
75. Vollmer S, Menssen A, Trommler P, Schendel D, Prinz JC. T lymphocytes derived from skin lesions of patients with psoriasis vulgaris express a novel cytokine pattern that is distinct from that of T helper type 1 and T helper type 2 cells. Eur J Immunol. 1994;24:2377-2382.
76. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood. 1996;87:2095-2147.
77. Arend WP, Guthridge CJ. Biological role of interleukin 1 receptor antagonist isoforms. Ann Rheum Dis. 2000;59;suppl. 1:i60-i64.
78. Subramaniam S, Stansberg C, Cunningham C. The interleukin 1 receptor family. Dev Comp Immunol. 2004;28:415-428.
79. Robb RJ, Smith KA. Heterogenecity of human T-cell growth factor(s) due to variable glycosylation. Mol Immunol. 1981; 18:1087-1094.
80. Smith KA. IL-2. In: Oppenheim JJ et al., Eds. Cytokine reference. T.1, San Diego:Academic Press, 2000;113.
81. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol. 1993;11:245-267.
82. Gołab J, Jakóbisiak M, Lasek W. Immunologia. Warszawa: Wydawnictwo Naukowe PWN, 2006.
83. Kemmett D, Symons JA, Colver GB, Duff GW. Serum-soluble interleukin 2 receptor in psoriasis. Failure to reflect clinical improvement. Acta Derm Venereol. 1990;70:264-267.
84. Takematsu H, Tagami H. Interleukin 2 soluble interleukin 2 receptor, and interferon- in the suction blister fluids from psoriatic skin. Arch Dermatol Res. 1990;282:149-152.
85. Powers R, Garrett DS, March CJ, Frieden EA, Gronenborn AM, Clore GM. Three-dimensional solution structure of human IL-4 by multidimensional heteronuclear magnetic resonance spectroscopy. Science. 1992;256:1673-1677.
86. Wlodawer A, Pavlovsky A, Gustchina A. Crystal structure of human recombinant IL-4 at 2,25 A resolution. FEBS Lett. 1992;309:59-64.
87. de Vries JE, Punnonen J. Interleukin-4 and Interleukin-13. In: Snapper CM, Ed. Cytokine regulation of humoral immunity-basic and clinical aspects, Chichester: John Wiley & Sons, 1996;195-215.
88. Idzerda RL, March CJ, Mosley B, et al. Human interleukin 4 receptor confers biological responsiveness and defines a novel receptor superfamily. J Exp Med. 1990;171:861-873.
89. Kondo M, Takeshita T, Ishii N, et al. Sharing of the interleukin-2 (IL-2) receptor chain between receptors for IL-2 and IL-4. Science. 1993;262:1874-1877.
90. Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor chain: a functional component of the interleukin-7 receptor. Science. 1993;262:1877-1880.
91. Zurawski SM, Chomarat P, Djossou O, et al. The primary binding subunit of the human interleukin-4 receptor is also a component of the interleukin-13 receptor. J Biol Chem. 1995; 270:13869-13878.
92. Roliński J. Importance of cytokines and their receptors. In: Lymphocytes apoptosis In patients with chronic B-cell leukemia: habilitation thesis. Lublin, Akademia Medyczna 1998.
93. Bazan J. Haematopoietic receptors and helical cytokines. Immunol Today. 1990;11:350-354.
94. Hirano T, Fukada T. IL-6 ligand and receptor family. In: Oppenheim JJ et al., Eds. Cytokine reference. T.1, San Diego: Academic Press, 2000;521-563.
95. Du XX, Wiliams DA. Interleukin-11: review of molecular, cell biology, and clinical use. Blood. 1997;89:3897-3908.
96. Du XX, Williams DA. Interleukin-11: a multifunctional growth factor derived from the hematopoietic microenvironment. Blood. 1994;83:2023-2030.
97. Keith JC, Albert A, Sonis ST, Pfeiffer CJ, Schaub RG. IL-11 a pleiotropic cytokine: exciting new effects of IL-11 on gastrointestinal mucosal biology. Stem Cells. 1994;12;suppl. 1: 79-90.
98. Keith CK Jr. IL 11. In: Oppenheim JJ et al., Eds. Cytokine reference. T.1, San Diego: Academic Press, 2000;565-584.
99. Spitz H. IL-7. In: Oppenheim JJ et al., Eds. Cytokine reference. T.1, San Diego: Academic Press, 2000;137-153.
100. Noguchi M, Nakamura Y, Russell SM, et al. Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor. Science. 1993;262:1877-1880.
101. Horuk R. The interleukin-8 receptor family: from chemokines to malaria. Immunol Today. 1994;15:169-174.
102. de Waal Malefyt R. IL-10. In: Oppenheim JJ et al., Eds. Cytokine reference. T.1, San Diego: Academic Press, 2000;165-185.
103. Hsu DH, De Waal Malefyt R, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1. Science. 1990;250:830-832.
104. Zdanov A, Schalk-Hihi C, Menon S, Moore KW, Wlodawer A. Crystal structure of Epstein-Barr virus protein BCRF1, a homolog of cellular interleukin-10. J Mol Biol. 1997;268: 460-467.
105. Rode HJ, Bugert JJ, Handermann M, et al. Molecular characterization and determination of the coding capacity of the genome of equine herpesvirus type 2 between the genome coordinates 0.235 and 0.258 (the EcoRI DNA fragment N;4.2kbp). Virus Genes. 1994;9:61-75.
106. Fleming SB, McCaughan CA, Andrews AE, Nash AD, Mercer AA. A homolog of interleukin-10 is encoded by the poxvirus orf virus. J Virol. 1997;71:4857-4861.
107. Zdanov A, Schalk-Hihi C, Gustchina A, Tsang M, Weatherbee J, Wlodawer A. Crystal structure of interleukin-10 reveals the functional dimer with an unexpected topological similarity to interferon gamma. Structure. 1995;3:591-601.
108. Asadullah K, Sabat R, Wiese A, Döcke WD, Volk HD, Sterry W. Interleukin-10 in cutaneous disorders: implications for its pathophysiological importance and therapeutic use. Arch Dermatol Res. 1999;291:628-636.
109. Asadullah K, Sabat R, Friedrich M, Volk HD, Sterry W. Interleukin-10: an important immunoregulatory cytokine with major impact on psoriasis. Curr Drug Targets Inflamm Allergy. 2004;3:185-192.
110. Kobayashi M, Fitz L, Ryan M, et al. Identification and purification of natural killer cell stimulatory factor (NKSF), a cytokine with multiple biologic effects on human lymphocytes. J Exp Med. 1989; 170:827-845.
111. Barrie AM, Plevy SE. The interleukin-12 family of cytokines: Therapeutic targets for inflammatory disease mediation. Clin Appl Immunol Rev. 2005;5:225-240.
112. Chua AO, Chizzonite R, Desai BB, et al. Expression cloning of a human IL-12 receptor component: a new member of the cytokine receptor superfamily with strong homology to gp130. J Immunol. 1994;152:128-136.
113. Presky DH, Yang H, Minetti LJ, et al. A functional interleukin 12 receptor complex is composed of two beta-type cytokine receptor subunits. Proc Natl Acad Sci USA. 1996; 93:14002-14007.
114. D'Andrea A, Rengaraju M, Valiante NM, et al. Production of natural killer cell stimulatory factor (interleukin-12) by peripheral blood mononuclear cells. J Exp Med. 1992;176: 1387-1398.
115. Shaker OG, Moustafa W, Essmat S, Abdel-Halim M, El-Komy M. The role of interleukin-12 in the pathogenesis of psoriasis. Clin Biochem. 2006;39:119-125.
116. Ling P, Gately MK, Gubler U, et al. Human IL-12 p40 homodimer binds to the IL-12 receptor but does not mediate biologic activity. J Immunol. 1995;154:116-127.
117. Waldmann T, Tagaya Y. The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol. 1999;17:19-49.
118. Waldmann TA, Tagaya Y. Interleukin-15. In: Oppenheim JJ et al., Eds. Cytokine reference. T.1, San Diego: Academic Press, 2000;213-223.
119. Giri JG, Ahdieh M, Eisenman J, et al. Utilization of the β and γ chains of the IL-2 receptor by the novel cytokine IL-15. EMBO J. 1994;13:2822-2830.
120. Giri JG, Kumaki S, Ahdieh M, et al. Identification and cloning of a novel IL-15 binding protein that is structurally related to the α chain of the IL-2 receptor. EMBO J. 1995;14:3654-3663.
121. Tagaya Y, Burton JD, Miyamoto Y, Waldmann TA. Identification of a novel receptor/signal transduction pathway for IL-15/T in mast cells. EMBO J. 1996;15:4928-4939.
122. Budagian V, Bulanova E, Orinska Z, et al. A promiscuous liaison between IL-15 receptor and Ax1 receptor tyrosine kinase in cell death control. EMBO J. 2005;24:4260-4270.
123. Witowski J, Ksiazek K, Jörres A. Interleukin-17: a mediator of inflammatory responses. Cell Mol Life Sci 2004;61:567-579.
124. Teunissen MBM, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-γ synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol. 1998;111:645-649.
125. Yao Z, Painter SL, Fanslow WC, et al. Human IL-17: a novel cytokine derived from T cells. J Immunol. 1995;155:5483-5486.
126. Dumont FJ. IL-17 cytokine/receptor families: emerging targets for the modulation of inflammatory responses. Expert Opin Ther Patents. 2003;13:287-303.
127. Silva WA, Jr., Covas DT, Panepucci RA, et al. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells. 2003;21:661-669.
128. Gracie JA, Robertson SE, McInnes IB. Interleukin-18. J Leukoc Biol. 2003;73:213-224
129. Dinarello CA. Interleukin 1 and interleukin 18 as mediators of inflammation and the aging process. Am J Clin Nutri. 2006;83:447S-455S.
130. Okamura H, Tsutsui H, Kashiwamura S, Yoshimoto T, Nakanishi K. IL-18. In: Oppenheim JJ et al., Eds. Cytokine reference. T.1, San Diego:Academic Press, 2000; 337-350
131. Torigoe K, Ushio S, Okura T, et al. Purification and Characterization of the Human Interleukin-18 Receptor. J Biol Chem. 1997;272:25737-25742.
132. Nakanishi K, Yoshimoto T, Tsutsui H, Okamura H. Interleukin-18 regulates both Th1 and Th2 responses. Annu Rev Immunol. 2001;19:423-474.
133. Gallagher G, Eskdale J, Jordan W, et al. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol. 2004;4:615-626
134. Blumberg H, Conklin D, Xu WF, et al. Interleukin 20: discovery, receptor identification, and role in epidermal function. Cell. 2001;104:9-19.
135. Koks S, Kingo K, Rätsep R, Karelson M, Silm H, Vasar E. Combined haplotype analysis of the interleukin-19 and -20 genes: relationship to plaque-type psoriasis. Genes Immun. 2004;5:662-667.
136. Dumoutier L, Leemans C, Lejeune D, Kotenko SV, Renauld JC. STAT activation by IL-19, IL-20 and mda-7 through IL-20 receptor complexes of two types. J Immunol. 2001;167:3545-3549.
137. Wang M, Tan Z, Zhang R, Kotenko SV, Liang P. Interleukin 24 (MDA-7/ MOB-5) signals through two heterodimeric receptors, IL-22R1/IL-20R2 and IL-20R1/IL-20R2. J Biol Chem. 2001;277:7341-7347.
138. Parrish-Novak J, Xu W, Brender T, et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor -ligand interactions mediate unique biological functions. J Biol Chem. 2002;277:47517-47523.
139. Levings MK, Sangregorio R, Sartirana C, et al. Human CD25+ CD4+ T suppressor cell clones produce transforming growth factor beta, but not interleukin 10, and are distinct from type 1 T regulatory cells. J Exp Med. 2002;196:1335-1346.
140. Rich BE, Kupper TS. Cytokines: IL-20 - a new effector in skin inflammation. Curr Biol. 2001;11:R531-R534.
141. Otkjaer K, Kragballe K, Funding AT, et al. The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. Br J Dermatol. 2005;153: 911-918.
142. Kingo K, Köks S, Nikopensius T, Silm H, Vasar E. Polymorphisms in the interleukin-20 gene: relationships to plaque-type psoriasis. Genes Immun. 2004;5:117-121.
143. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715-725.
144. Blauvelt A. Fill court press on psoriasis. J Invest Dermatol. 2004;123:7-8
145. Parham C, Chirica M, Timans J, et al. A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R. J Immunol. 2002;168:5699-5708.
146. Wiekowski MT, Leach MW, Evans EW, et al. Ubiquitous transgenic expression of the IL-23 subunit p19 induces multiorgan inflammation, runting, infertility, and premature death. J Immunol. 2001;166:7563-7570.
147. Cua D J, Sherlock J, Chen Y, et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature. 2003;421:744-748.
148. Bastos KRB, Marinho CRF, Barboza R, Russo M, Álvarez JM, D'Império Lima MR. What kind of message does IL-12/IL-23 bring to macrophages and dendritic cells? Microbes Infect. 2004;6:630-636.
149. Goetz FW, Planas JV, MacKenzie S. Tumor necrosis factor. Dev Comp Immunol. 2004;28:487-495.
150. Schottelius AJG, Moldawer LL, Dinarello CA, Asadullah K, Sterry W, Edwards III CK. Biology of tumor necrosis factor-α - implicatious for psoriasis. Exp Dermatol. 2004;13:193-222.
151. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5:392-399.
152. Aderka D. The potential biological and clinical significance of the soluble tumor necrosis factor receptors. Cytokine Growth Factor Rev. 1996;7:231-240.
153. Makhatadze NJ. Tumor Necrosis Factor Locus: Genetic Organisation and Biological Implications. Human Immunol. 1998;59:571-579.
154. Ware CF. The TNF superfamily. Cytokine Growth Factor Rev. 2003;14:181-184
155. Numerof RP, Asadullach K. Cytokine and Anti-Cytokine Therapies for Psoriasis and Atopic Dermatitis. Biodrugs. 2006;20:93-103.
156. Billiau A, Vandenbroeck K. IFN γ. In: Cytokine reference. T.1. Ed.J.J. Oppenheim et al., Academic Press San Diego. 641-688, 2000.
157. Mühl H, Pfeilschifter J. Anti-inflammatory properties of pro-inflammatory interferon-gamma. International Immunopharmacology. 2003;3:1247-1255.
158. Menter A. Recent Advances in Psoriasis Therapy and the Work of the International Psoriasis Council. In: Business Briefing: US Dermatology Review 2006: 23-27.
159. Gibbs A, Markham T, Walsh C, Bresnihan B, Veale D, FitzGerald O. Anakinra (Kineret) in psoriasis and psoriatic arthritis: a single-center, open-label, pilot study. Arthritis Res Ther. 2005;7;suppl. 1:P68.
160. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: The new therapeutic frontier. Arch Dermatol. 2002;138: 657-663.